NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

Search Plan my trip
NASDAQ / LIVE COMPANY INTELLIGENCE

Abeona Therapeutics Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERABEO
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / ABEO COVERAGE

What’s moving Abeona Therapeutics Inc. now

Current reporting with the operating signal separated from the noise.

01
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

The development tests whether Abeona Therapeutics Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
02
Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript

Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript

Investors are testing whether Abeona Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript

Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript

Investors are testing whether Abeona Therapeutics Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Abeona Therapeutics Inc. Joins Russell 2000® and 3000® Indexes Amid Positive Momentum from ZEVASKYN™ Approval

Abeona Therapeutics Inc. Joins Russell 2000® and 3000® Indexes Amid Positive Momentum from ZEVASKYN™ Approval

The story matters when it changes Abeona Therapeutics Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Abeona Therapeutics Inc. Advances pz-cel BLA Review with FDA, Anticipates Commercial Launch for RDEB Treatment by Q3 2025

Abeona Therapeutics Inc. Advances pz-cel BLA Review with FDA, Anticipates Commercial Launch for RDEB Treatment by Q3 2025

The development tests whether Abeona Therapeutics Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest ABEO filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-13 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-13 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-03-17 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-09-15 · Period 2026-09-15SEC ↗8-KMaterial company eventFiled 2026-08-13 · Period 2026-08-13SEC ↗8-KMaterial company eventFiled 2026-06-12 · Period 2026-06-12SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-27 · Period 2026-04-27SEC ↗4Official SEC filingFiled 2026-09-01 · Period 2026-09-01SEC ↗
EARNINGS / QUARTERLY TRACKER

Abeona Therapeutics Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.